<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) is a systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, with a more aggressive course in young males </plain></SENT>
<SENT sid="1" pm="."><plain>Orogenital <z:mpath ids='MPATH_579'>ulcers</z:mpath>, <z:hpo ids='HP_0000554'>uveitis</z:hpo> and cutaneous lesions are the most frequent manifestations </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab </plain></SENT>
<SENT sid="3" pm="."><plain>We observed a good clinical response in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab </plain></SENT>
</text></document>